UK Health Secretary Wes Streeting has made a call for 'cross-party consensus' on gender identity services ahead of the highly anticipated trial of puberty blockers in children. In a letter to Conservative leader Kemi Badenoch, Streeting urged her to put aside ideology and take the heat out of debate over the issue.
The trial, which is worth Β£10.7m, aims to study the effects of puberty blockers on over 200 children presenting with gender identity conditions as part of a wider research project on possible treatment pathways. The trial is the result of recommendations from a report by leading paediatrician Hilary Cass, who found "remarkably weak" evidence that puberty blockers are effective in treating gender-related distress.
Streeting expressed his concerns about the potential impact of the medication on children's development, but also acknowledged the need for clinical trials to inform decision-making. He stated that while he was "deeply uncomfortable" with the idea of delaying a natural part of human development, it was essential to follow evidence-based advice and take the heat out of debate.
The Conservative leader and shadow health secretary Stuart Andrew had previously raised concerns about the trial, citing potential side effects such as infertility and loss of sexual function. However, Streeting argued that these were valid concerns, but also pointed out that a lack of proper control groups in the trial could create bias.
In response to Andrew's claims, Streeting stated that this was not accurate, as researchers would be comparing trial participants with children who did not receive puberty blockers. He emphasized the importance of maintaining a cross-party consensus on gender identity services and ensuring that children's health is led by evidence and medical expertise.
The debate over gender identity services has become increasingly polarized in recent years, but Streeting's intervention aims to bring some much-needed balance to the discussion. By urging his fellow politicians to put aside ideology and focus on the wellbeing and safety of children, he is hoping to create a more constructive environment for decision-making about this sensitive issue.
The trial, which is worth Β£10.7m, aims to study the effects of puberty blockers on over 200 children presenting with gender identity conditions as part of a wider research project on possible treatment pathways. The trial is the result of recommendations from a report by leading paediatrician Hilary Cass, who found "remarkably weak" evidence that puberty blockers are effective in treating gender-related distress.
Streeting expressed his concerns about the potential impact of the medication on children's development, but also acknowledged the need for clinical trials to inform decision-making. He stated that while he was "deeply uncomfortable" with the idea of delaying a natural part of human development, it was essential to follow evidence-based advice and take the heat out of debate.
The Conservative leader and shadow health secretary Stuart Andrew had previously raised concerns about the trial, citing potential side effects such as infertility and loss of sexual function. However, Streeting argued that these were valid concerns, but also pointed out that a lack of proper control groups in the trial could create bias.
In response to Andrew's claims, Streeting stated that this was not accurate, as researchers would be comparing trial participants with children who did not receive puberty blockers. He emphasized the importance of maintaining a cross-party consensus on gender identity services and ensuring that children's health is led by evidence and medical expertise.
The debate over gender identity services has become increasingly polarized in recent years, but Streeting's intervention aims to bring some much-needed balance to the discussion. By urging his fellow politicians to put aside ideology and focus on the wellbeing and safety of children, he is hoping to create a more constructive environment for decision-making about this sensitive issue.